Figure 1:
Overall survival in the 38 evaluable patients enrolled on AAML07P1 combining bortezomib with either idarubicin/low-dose cytarabine (Arm A) or bortezomib with high-dose cyatarabine (1g/m2/dose) and etoposide.
Overall survival in the 38 evaluable patients enrolled on AAML07P1 combining bortezomib with either idarubicin/low-dose cytarabine (Arm A) or bortezomib with high-dose cyatarabine (1g/m2/dose) and etoposide.
